Search

Tegafur

Tegafur is usually given in combination with other drugs that enhance the bioavailability of the 5-FU by blocking the enzyme responsible for its degradation, or serves to limit the toxicity of 5-FU by … It is a pyrimidine analogue used in combination therapies as an active chemotherapeutic agent in conjunction with [DB09257] and [DB03209], or along with [DB00544] as [DB09327].

Azatadine

Antihistamines such as azatadine appear to compete with histamine for histamine H1- receptor sites on effector cells.

Captopril

Captopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII).

Debrisoquine

It is also noteworthy in being a substrate for a polymorphic cytochrome P-450 enzyme.

Zucapsaicin

Zucapsaicin has also been evaluated for the management of several conditions manifested by chronic nerve pain. … It is a modulator of transient receptor potential cation channel subfamily V member 1 (TRPV-1), also known as the vanilloid or capsaicin receptor 1, that reduces pain and improves articular functions.

Zafirlukast

Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. … Zafirlukast blocks the action of the cysteinyl leukotrienes on the CysLT1 receptors, thus reducing constriction of the airways, build-up of mucus in the lungs and inflammation of the breathing passages

Macimorelin

They include treatment for growth retardation in children and cachexia associated with chronic disease such as AIDS and cancer. … Macimorelin, developed by Aeterna Zentaris, was approved by the FDA in December 2017 under the market name Macrilen for oral solution.

Hydrocodone

The FDA first approved Hydrocodone for use as part of the cough suppressant syrup Hycodan in March of 1943.[L9025]

Borneol

Lenalidomide

[A228708] Available as oral capsules, lenalidomide is approved by the FDA and EU for the treatment of multiple myeloma, myelodysplastic syndromes, mantle cell lymphoma, follicular lymphoma, and marginal